SYF9b6f554ff5504f69b1ff7dc284a9cfccRegistry ID: 2024-511949-19-00|UnknownPhase 1
Loading search results
interventional
N/A
4 countries
11
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 30, 2024
Actual (reported)Hospital Universitario 12 De Octubre
Madrid, 28041, Spain
Hospital General Universitario Gregorio Maranon
Madrid, 28009, Spain
Hospital Clinic De Barcelona
Barcelona, 08036, Spain
Institut Gustave Roussy
Villejuif, 94800, France
Laura Lassouw
First Submitted
April 30, 2024
Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma
Hopital Saint Louis
Paris, 75010, France
Centre Hospitalier Regional De Marseille
Marseille, 13005, France
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
Warsaw, 02-781, Poland
Istituto Europeo Di Oncologia S.r.l.
Milan, 20141, Italy
Azienda Ospedaliera Universitaria Senese
Siena, 53100, Italy
Istituto Oncologico Veneto
Padova, 35128, Italy
IRCCS Istituto Nazionale Tumori Fondazione Pascale
Naples, 80131, Italy